International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 831-838 , 1 November 2007

Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme

  • Judith M. Ford, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • Corresponding Author InformationReprint requests to: Judith M. Ford, M.D., Ph.D., c/o Anne Wagner, Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, 200 UCLA Medical Plaza, Suite B265, Los Angeles, CA 90095-6951. Tel: (310) 825-6577; Fax: (310) 794-9795
    • ,
  • Wendy Seiferheld, M.S.

      Affiliations

    • Radiation Therapy Oncology Group Statistical Unit, Philadelphia, PA
    • ,
  • Jeffrey R. Alger, Ph.D.

      Affiliations

    • Department of Radiology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • ,
  • Genevieve Wu, Ph.D.

      Affiliations

    • Department of Radiology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • ,
  • Thyra J. Endicott, M.D.

      Affiliations

    • Department of Radiation Oncology, Torrance Memorial Medical Center, Torrance, CA
    • ,
  • Minesh Mehta, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Wisconsin School of Medicine, Madison, WI
    • ,
  • Walter Curran, M.D., F.A.C.R.

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
    • ,
  • See-Chun Phan, M.D.

      Affiliations

    • Pharmacyclics Inc., Sunnyvale, CA

Received 2 August 2006 ,Revised 4 April 2007 ,Accepted 13 April 2007.

References 

  1. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg. 1978;49:333–343
  2. Neider C, Andratschke N, Wiedenmann N, et al. Radiotherapy for high-grade gliomas: Does altered fractionation improve the outcome?. Strahlenther Onkol. 2004;180:401–407
  3. Buckner JC, Michalak JC, Burton GV, et al. A Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 trials. J Clin Oncol. 2006;24:3871–3879
  4. Mehta M, O'Neill A, Grunnet M, et al. A Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group trial 2394. J Clin Oncol. 2003;21:1485–1491
  5. Medical Research Council . Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19:509–518
  6. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta- analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018
  7. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–2597
  8. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation Therapy Oncology Group study 83-02. Cancer. 1996;77:1535–1543
  9. Stupp R, Mason WP. van den Bent MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–986
  10. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–2569
  11. Mutter N, Stupp R. Temozolomide: A milestone in neuro-oncology and beyond?. Expert Rev Anticancer Ther. 2006;6:1187–1204
  12. Mody TD, Fu L, Sessler JL. Texaphyrins: Synthesis and development of a novel class of therapeutic agents. In:  Karlin KD editors. Progress in inorganic chemistry. New York: John Wiley & Sons, Inc.; 2001;p. 551–598
  13. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19:2074–2083
  14. Sessler JL, Miller RA. Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol. 2000;59:733–739
  15. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium (Gd-Tex) enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys. 2001;51:1025–1036
  16. Magda D, Gerasimchuk N, Lecane P, et al. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun. 2002;22:2730–2731
  17. Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res. 2001;7:3215–3221
  18. Rockwell S, Donnelly E, Liu Y, et al. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys. 2002;54:536–541
  19. Xu S, Zakian K, Thaler H, et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys. 2001;49:1381–1390
  20. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. [published correction appears in Proc Natl Acad Sci USA 1999;96:2569] Proc Natl Acad Sci USA. 1996;93:6610–6615
  21. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20:3445–3453
  22. Mehta MP, Rodrigus P, Terhaard C, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–2536
  23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  24. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187–220
  25. Ford JM, Endicott TE, Alger JR, et al. Uptake of the radiation sensitizer gadolinium texaphyrin by glioblastoma multiforme: Proceedings of the American Society for Therapeutic Radiology and Oncology 1999 meeting. [Abstract] Int J Radiat Oncol Biol Phys. 1999;45(Suppl.):320–321
  26. Wu GN, Ford JM, Alger JR. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol. 2006;77:95–103
  27. Wu GN, Ford JM, Alger JR. The radiation enhancer motexafin gadolinium (MGd) does not penetrate the intact blood brain barrier in glioblastoma multiforme patients undergoing post-operative radiation therapy: Proceedings of the American Society for Therapeutic Radiology and Oncology meeting. [Abstract] Int J Radiat Oncol Biol Phys. 2003;57(Suppl.):329–330
  28. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astroctyomas: A simple and reproducible method. Cancer. 1988;62:2152–2165
  29. Miller RA, Woodburn K, Fan Q, et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 1999;45:981–989
  30. Ford JM, Seiferheld W, Mehta M, et al. Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) with glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG GBM database. [Abstract] Proc Am Soc Clin Oncol. 2003;22:106

 Research supported by the National Cancer Institute Cancer Therapy Evaluation Program (Grant RO3 CA 78170); National Institutes of Health supplement to UCLA Johnson Comprehensive Cancer Center Core grant; National Institutes of Health General Clinical Research Center, UCLA (Grant M01-RR00865), General Clinical Research Centers Program; and Pharmacyclics Inc. Comparative analysis supported by the Radiation Therapy Oncology Group (Grants U10 CA21661, CCOP U10 CA37422), and Stat U10 CA32115 from the National Cancer Institute.

 The contents of this manuscript are the sole responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

 Conflict of interest: S.-C. Phan is employed by, and owns stock in, Pharmacyclics, Inc.; J. Ford, M. Mehta, J. Alger, and G. Wu have each received research funding from Pharmacyclics, Inc.; W. Seiferheld, T. Endicott, and W. Curran have no conflicts of interest.

PII: S0360-3016(07)00680-3

doi: 10.1016/j.ijrobp.2007.04.017

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 831-838 , 1 November 2007

Article Tools

* Image Usage & Resolution